Revenue from the Sales of Chronic Plaque Psoriasis Therapeutics Market to Increase Exponentially During 2018 2026 – Cole of Duty

Psoriasis is an autoimmune disease which is characterized by scaly patches of skin with inflammation and causes excessive production of new skin cells. Presently, there are no long term therapeutics available for the treatment of psoriasis. Chronic Plaque psoriasis is the one of the most common type of psoriasis. This disease condition is associated with several risk factors such as infection, psychological stress and others. Diagnosis of chronic plaque psoriasis is based on clinical appearance, is the case is severe then biopsy is recommended by the healthcare professionals in order to distinguish it from other conditions such as seborrheic dermatitis, ichen simplex chronicus and others.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/21442

Increasing uptake of biological drugs is one of the major factor propelling the growth of the global chronic plaque psoriasis therapeutics market. Advances in inflammation and immunology research, introduction of innovative drugs and increased focus on the usage of combination therapies are further accentuating the demand for chronic plaque psoriasis drugs. Adverse side effects, however, side-effects associated with the treatment such as risk of skin cancer, headache, hair loss, suppression of immunity and others could pose a major threat to the global chronic plaque psoriasis therapeutics market. Ixekizumab, tofacitinib, baricitinib, tregalizumab, ponesimod, AbGn-168H, E-6201, briakinumab, adalimumab and others are some of the drugs currently in clinical trials for the treatment of chronic plaque psoriasis.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/21442

Geographically, North America forms the largest regional market for chronic plaque psoriasis therapeutics. In addition, developed countries such as Germany, France, Spain, Italy, the U.K and Japan accounts for the second largest share of the global chronic plaque psoriasis therapeutics market due to emergence of new formulations.

The key manufacturers engaged in developing the chronic plaque psoriasis therapeutics market include Abbvie, Inc., Novartis International AG, Pfizer, Inc., Merck & Co., Astelllas Pharma, Inc., GlaxoSmithKline Plc and others.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/21442

Go here to read the rest:

Revenue from the Sales of Chronic Plaque Psoriasis Therapeutics Market to Increase Exponentially During 2018 2026 - Cole of Duty

Psoriasis Drugs Market 2028 Key Insights and COVID-19 Business Impact – 3rd Watch News

The growth of thepsoriasis drugs marketis attributed to the growing use of topical corticosteroids products and psoriasis treatment across the globe. According to a latest research by the company, the global corticosteroid psoriasis drugs treatment market is expected to account for over US$ 6,509 Mn in terms of value by 2028 end.

The report projects that the psoriasis drugs treatment market will witness significant growth with average year-on-year growth rate pegged at 7.1% through 2028. The report lists out the key points being considered by the manufacturers of psoriasis drugs to emerge and gain profit in the long run in psoriasis drugs market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25102

Company Profile

The North America psoriasis drugs market is expected to expand at significant CAGR and to be the dominant revenue-generating psoriasis drugs market due to large presence of dermatology clinics and facilities. Europe is also expected to be one of the leading regional markets for psoriasis drugs as most of the major academic research institutes are located in the region.

Psoriasis Drugs Market: Analysis

Combination therapeutics and product innovations and are factors expected to drive the need for easy and non-invasive treatment for patients undergoing psoriasis treatment and thus, will lead to greater product penetration in the psoriasis drugs treatment market. In this regard, the National Psoriasis Foundation reported that in 2016, around 1,200 patients in the U.S. opted for new combinational therapies.

The use of psoriasis drugs in combination with other therapies for treating psoriasis is far more effective in the long run. To minimize side effects associated with psoriasis drugs, such as hypertension, swelling, rashes, and inflammatory bowel disease caused by traditional drugs, physicians often suggest the use of combination therapies along with psoriasis drugs.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25102

Using the treatment has a positive impact on the patient. This factor is expected to fuel the demand for psoriasis drugs used in combination and consequently boost the growth of the psoriasis drugs market.

Plaque psoriasis is the first most prominent type of segment in the global psoriasis drugs market. Approximately 90% of psoriasis types are chronic plaque psoriasis, which are characterized by red patches covered with a whitish buildup of dead cells, and are well-demarcated, thick, often symmetrically distributed scaly red plaques.

Although the plaques can affect any part of the skin, they are majorly found on the surface of the elbows, knees and scalp. According to the WHO, 92% patients with psoriasis suffer from severe scaling of skin, especially found in plaque psoriasis.

The global psoriasis drugs market is segmented based on product type, drug class, disease indication, and distribution channel. Based on product type, the psoriasis drugs market has been segmented into topical, oral, and injectable.

The topical product type segment in psoriasis drugs market is expected to be the dominant segment holding maximum share in the global psoriasis drugs market as they are mostly preferred by the patients. Topical psoriasis drugs are applied to the skin in an easy way and are generally the first line of defense in treating psoriasis.

Topicals normalize excessive cell reproduction and reduce psoriasis inflammation. Topicals are lotions, creams, gels, ointments and shampoos. Patients with mild psoriasis are able to tackle their skin complaint with topical treatment. Moderate to severe psoriasis mainly needs additional therapy or oral psoriasis drugs.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25102

Based on distribution channel, the psoriasis drugs market has been segmented into retail pharmacies, hospital pharmacies and e-commerce.

In terms of revenue, the retail pharmacies segment dominated the global psoriasis drugs market in 2017 and is projected to continue to do so throughout the forecast period. The retail pharmacies segment in psoriasis drugs market is expected to hold a large share in the psoriasis drugs treatment market.

In terms of revenue, the drug class segment in the global psoriasis drugs market is expected to hold significant share over the forecast period. Besides, the segment is expected to exhibit large investment opportunities for companies operating in psoriasis drugs market throughout the forecast period.

Read more from the original source:

Psoriasis Drugs Market 2028 Key Insights and COVID-19 Business Impact - 3rd Watch News

Global North America and Europe Phototherapy Treatment Market is Poised to Register 6% Growth by the End of 2026 – 3rd Watch News

The opportunity analysis covered to understand the North America and Europe phototherapy treatment market for acne and psoriasis, makes this new publication an exclusive one. After a thorough study of the market, our expert team of analysts in the healthcare domain went the extra mile to offer in-depth insights into the market. While studying the market the first important feature we have observed is that this market is likely to witness moderate growth during the 10 year projected period. After a detailed study of the future scenario of the overall market, it was easy for our analysts to identify the macroeconomic factors such as the economic burden of skin diseases and societal habits influencing the phototherapy treatment market for acne and psoriasis in North America and Europe. The report titled Phototherapy Treatment Market for Acne and Psoriasis: North America and Europe Industry Analysis 2012 2016 and Opportunity Assessment 2017 2027 provides detailed information on how the lack of robust clinical evidence on various disease conditions is limiting the growth of the phototherapy treatment market for acne and psoriasis in the regions of North America and Europe.

Request Report [emailprotected]https://www.futuremarketinsights.com/reports/sample/rep-gb-na-4297

One astonishing fact we have come across while inspecting this market is that even in the most developed regions such as North America and Europe, not much research has been done on the other light therapies used in the treatment of acne and psoriasis conditions except blue light and UVB therapy. On the other hand while covering the disease epidemiology we have observed that prevalent cases of acne and psoriasis were remarkable in both the regions especially Europe in 2015.

Is the home-based phototherapy system a solution to limit the rising incidents of the disease?

Usually, phototherapy is an office based treatment procedure. However, lack of sufficient phototherapy units and the majority of phototherapy centres being located in urban areas are forcing patients to choose alternative treatments for their dermatological conditions. An increasing adoption of home-based phototherapy systems is creating huge opportunities for manufacturers. Home based phototherapy reduces patient hassles like transportation issues and the long waiting time in clinics, among others. In addition to this, it also reduces the direct and indirect medical costs of patients.

Our unique analysis of the classification of markets in various segments

According to our analysis, North America represents the most lucrative market, followed by Western Europe and Eastern Europe.

Hospitals end user segment dominates the global market; however, home care settings are becoming the choice of service for patientsBlue light therapy is gaining more traction in phototherapy owing to its benefits in treating acnePlaque psoriasis sub-segment dominates the market in the psoriasis disease segment due to rise in psoriasis patient populationInternational monoclonal antibody conference reports our key source while researching this market

While inspecting the North America and Europe phototherapy treatment market for acne and psoriasis in detail, we have referred to the annual reports, publications, and presentations of product providers. Our analysts have also considered key winning strategies followed by phototherapy treatment market for acne and psoriasis product manufacturers. We have carried out systematic and exhaustive secondary research to analyse the required data points to arrive at the overall market numbers. Detailed questionnaires have been developed for each node in the value chain to extract the required market information through primary research interviews. Data acquired through research is represented using charts, infographics, presentation of key findings by region and providing strategic recommendations and actionable insights for critical decision making.

North America and Europe Phototherapy Treatment for Acne and Psoriasis Market Taxonomy

By Disease Type

Psoriasis

Guttate Psoriasis

Inverse Psoriasis

Pustular Psoriasis

Erythrodermic Psoriasis

Plaque Psoriasis

Acne

Acne Vulgaris

Acne Conglobata

Acne Fulminans

Gram-Negative Folliculitis

Acne Rosacea

Pyoderma Faciale

By Phototherapy Type

Blue Light Phototherapy

Red Light Phototherapy

Intense Pulsed Light (IPL) Phototherapy

Narrowband UVB Phototherapy

Psoralens+Ultravioletlight A (PUVA) Phototherapy

Request for [emailprotected]https://www.futuremarketinsights.com/askus/rep-gb-na-4297

By End User

Hospitals

Dermatology Clinics/Skin Care Centres

Wellness Centres

Home Care Settings

By Region

North America

Western Europe

Eastern Europe

View original post here:

Global North America and Europe Phototherapy Treatment Market is Poised to Register 6% Growth by the End of 2026 - 3rd Watch News

Obesity, but Not Metabolic Diseases, Is Associated With Risk of Psoriasis: A Population-Based Cohort Study in Taiwan – DocWire News

Background:Obesity and metabolic diseases including diabetes, hyperlipidemia, and hypertension are reportedly associated with an increased risk of psoriasis. However, few prospective studies have investigated the association of obesity and metabolic diseases with the risk of psoriasis.

Objective:To examine whether obesity or metabolic diseases increase the risk of psoriasis.

Methods:Participants were collected from 4 rounds (2001, 2005, 2009, and 2013) of the Taiwan National Health Interview Survey. Incident cases of psoriasis were identified from the National Health Insurance database. Participants were followed from the time of the National Health Interview Survey interview until December 31, 2017, or until a diagnosis of psoriasis was made or the participant died. The Cox regression model was used for the analyses.

Results:Of 60,136 participants, 406 developed psoriasis during 649,506 person-years of follow-up. Compared to participants with a BMI of 18.5-22.9, the adjusted hazard ratios (aHR) of psoriasis were 1.34 (95% CI 1.05-1.71) for a BMI of 25.0-29.9 and 2.70 (95% CI 1.95-3.72) for a BMI 30. Neither individual nor multiple metabolic diseases were associated with incident psoriasis. Participants with a BMI 30 were at significantly higher risk of both psoriasis without arthritis (aHR 2.60; 95% CI 1.85-3.67) and psoriatic arthritis (aHR 3.96; 95% CI 1.45-10.82).

Conclusion:Obesity, but not metabolic diseases, significantly increased the risk of psoriasis.

Keywords:Diabetes mellitus; Hyperlipidemia; Hypertension; Metabolic syndrome; Obesity; Psoriasis.

Excerpt from:

Obesity, but Not Metabolic Diseases, Is Associated With Risk of Psoriasis: A Population-Based Cohort Study in Taiwan - DocWire News

More SAEs With Biologic Agents vs Placebo in Treatment of Psoriasis? – Dermatology Advisor

The exclusion of patients with worsening psoriasis from meta-analyses of trials that examine biologic therapies for type-plaque psoriasis reveal that serious adverse events (SAEs) are higher with biologic therapies than placebo, which suggest that findings from many meta-analyses do not reflect the real-world safety of biologic agents for psoriasis. This is according to a study research published in the British Journal of Dermatology.

In this study, researchers from France analyzed 51 randomized clinical trials in the Living Network Cochrane Review that compared a biologic therapy to placebo in patients with moderate to severe plaque psoriasis who required systemic treatment (N=24,820).

Trials included in this analysis included 1 anti-tumor necrosis factor (TNF) alpha arm, 1 anti-interleukin (IL)-17 arm, 1 anti-IL-23 arm, and 1 anti-IL-12/23 arm. The primary outcome of the analysis included the number of SAEs with biologic agents vs placebo after cases of psoriasis worsening were excluded. An additional secondary outcome included the number of adverse events (AEs) of special interest.

The mean age of the overall population was 45 years, and the mean baseline PASI score was 20.5. A higher percentage of patients included in all 51 trial were men compared with women (69% vs 31%, respectively). Approximately 25% (n=6287) of the population were randomly assigned to a placebo group.

In the analysis that included cases of psoriasis worsening, there was no statistically significant difference between biologic therapies and placebo in terms of the risk for occurrence SAEs (risk ratio [RR], 1.09; 95% CI, 0.88-1.36; P =.43). When the investigators excluded cases of psoriasis worsening, however, biologicl therapy was associated with a significantly higher risk for SAEs (RR, 1.30; 95% CI, 1.02-1.65; P =.03).

Separated by drug classes, the analysis revealed RRs of 1.68 (95% CI, 1.11-2.54; P =.01) for anti-TNF-alpha, 1.28 (95% CI, 0.88-1.85; P =.20) for anti-IL-17, 0.95 (95% CI 0.59-1.52; P =.83) for anti-IL-23, and 1.18 (95% CI 0.72-1.94; P =.51) for anti-IL-12/23. The small number of AEs of special interest in these analyses prevented the researchers from examining this outcome.

According to the investigators, the reporting of psoriasis worsening has changed over time, which made indirect comparisons not possible by network meta-analysis.

Based on these findings, the investigators added that the results for SAEs overall and SAEs excluding disease worsening should be presented in the results of RCTs and so in systematic reviews and meta-analyses.

Reference

Afach S, Chaimani A, Evrenoglou T, et al. Meta-analysis results do not reflect the real safety of biologics in psoriasis [published online May 23, 2020]. Br J Dermatol. doi: 10.1111/bjd.19244

Read this article:

More SAEs With Biologic Agents vs Placebo in Treatment of Psoriasis? - Dermatology Advisor

Psoriasis, Fungal Infections, Are Common in Patients With COVID-19 – Dermatology Advisor

Psoriasis, superficial fungal infections, seborrheic dermatitis, actinic keratosis, and herpes simplex were the most common dermatologic diseases observed in patients with coronavirus disease 2019 (COVID-19) up to 3 years before their COVID-19 diagnosis, according to study research published in Dermatologic Therapy. Psoriasis was most common in the 3 months prior to a COVID-19 diagnosis in this study, which the researchers suggest could have been caused by the stress burden associated with the pandemic.

The retrospective study included 93 patients with COVID-19 (mean age, 55.2819.32 years) who had been admitted to a dermatology outpatient clinic in Turkey in the last 3 years before receiving a diagnosis of COVID-19. Patients were categorized as those who presented to the clinic in the last 3 months, 1 year, and 3 years prior to the COVID-19 diagnosis. A total of 6 patients from the overall cohort were in intensive care, whereas 4 became exitus.

Superficial fungal infections (25.8%), seborrheic dermatitis (11.8%), actinic keratosis (10.8%), psoriasis (6.5%), and eczema (6.5%) were the most common dermatologic conditions in the patients with COVID-19 who had dermatologic diseases 3 years prior to their infection. There were 52 patients with COVID-19 who visited a dermatology clinic for dermatologic diseases in the last year for superficial fungal infections (21.2%), seborrheic dermatitis (13.5%), actinic keratosis (11.5%), psoriasis (9.6%), herpes simplex (5.8%), and eczema (5.8%).

A total of 17 patients with COVID-19 (median age, 58 years) presented to a dermatology outpatient clinic for the last 3 months prior to their COVID-19 diagnosis. In these patients, the most common dermatologic diseases were superficial fungal infections (25%), psoriasis (20%), and viral skin diseases (15%).

Limitations of the study included the small sample size, retrospective design, and the inclusion of patients from a single center in Turkey.

Based on their findings, the researchers wrote that the potential similarity between cutaneous and mucosal immunity and immunosuppression suggests that patients with certain dermatologic diseases are particularly more vulnerable to the COVID-19.

Reference

Kutlu , Metin A. Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? [published online May 5, 2020]. Dermatol Ther. doi: 10.1111/dth.13509

Read the original here:

Psoriasis, Fungal Infections, Are Common in Patients With COVID-19 - Dermatology Advisor

Psoriasis injection okayed for limited use to treat COVID patients: Drug controller – Outlook India

New Delhi, Jul 10 (PTI) India''s drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.

Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.

"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome, an official told PTI.

"It is already an approved drug of Biocon for treating psoriasis for last many years," the official said.

Written informed consent of each patient is required before the use of this drug, he said. PTI PLB RAXRAX

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: PTI

Read the rest here:

Psoriasis injection okayed for limited use to treat COVID patients: Drug controller - Outlook India

Massive Growth in Psoriasis Treatment Market Set to Witness Huge Growth by 2026 | Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck…

Psoriasis Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Psoriasis Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=273738

Top Key Players Profiled in This Report:

Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck and Co. Inc., AbbVie and Amgen, Eli Lilly

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Psoriasis Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Psoriasis Treatment markets trajectory between forecast periods.

Get up to 20% Discount on this Premium[emailprotected]:

https://www.a2zmarketresearch.com/discount?reportId=273738

Reasons for buying this report:

Table of Contents:

Global Psoriasis Treatment Market Research Report

Chapter 1 Psoriasis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Psoriasis Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=273738

See the rest here:

Massive Growth in Psoriasis Treatment Market Set to Witness Huge Growth by 2026 | Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck...

My Psoriasis Doesnt Get in the Way of My Body Confidence – Yahoo Lifestyle

Photo credit: Hearst Owned

From Oprah Magazine

Millions of Americans have psoriasis, which can cause patches of red or scaly skin to appear around the body. And because these flare-ups can occur anywhereincluding the hands, legs, face, and neck, all of which can be difficult to covershame and embarrassment have traditionally been part and parcel of having the disease. But that's starting to change, partly thanks to efforts by women like Angelique Miles and Joni Kazantzis, who use blogs and social media platforms to advocate for psoriasis patients and work to destigmatize the condition. We recently caught up with both of them to discover how they changed their way of thinking about psoriasis and kicked self-consciousness to the curb. Their words will resonate with anyone struggling with their confidence, regardless of the skin they're in.

As a 13-year-old with psoriasis on her scalp and forehead, Angelique Miles did everything she could to hide it. At the time, there were no available medications to treat the disease. I had bangs and I remember a girl said to me once, You know you can still see it, Miles recalls. It was traumatizing.

That was the early 80s, and there wasnt that much doctors could do. Miles dermatologist at the time basically told her to try a tar shampoo on her scalp, and that was it. It wasnt until her twenties that Miles discovered NYUs medical center, where they had a specific division for psoriasis. She started going twice a week for UVB treatment and, through an ongoing process with her doctorand through lots of trial and errorMiles was able to find the right medications and biologics to keep flare-ups to a minimum and better control her psoriasis.

Here's how the former music publishing executive turned fitness influencer and health advocate rediscovered her confidence.

A therapist once told me that my skin is the largest organ and I have to learn to accept and love it, says Angelique. Thats not to say I could still do without my psoriasis, but I now wear dresses in the summer or go to the beach. Other people can tell if youre confident, and giving off that vibe makes them not notice your skin as much. Its liberating.

Story continues

It seems like everybody knows someone with it and celebrities are talking about it more and more, she says, so theres more awareness these days.

Fitness has always been a big part of my life and being in good shape really contributes to my confidence, says Angelique. I used to start every day at the gym, but recently I bought a Peloton bike and I also do some virtual training sessions and online workouts.

One morning, when Joni was 15, she woke up covered in spots. I had no symptoms before that, but my grandmother lived with us and she had psoriasis, so she knew what it was right away, she recalls. I was so young and insecure at the time, so it was a struggle back then.

Joni has continually worked with her doctor to find a medication that keeps her psoriasis mostly in check; she now injects a biologic every few weeks. She still has to work on managing triggers like stress that can cause it to reappear. The one silver lining to it all: Joni believes that being forced to grow up with psoriasis has made her stronger and more able to deal with it as an adult. Heres her approach.

I make sure that whatever I wear feels good, nothing too tight or made with a synthetic material that irritates my skin, says Joni.

In the summer, I live in maxi dresses, says Joni. They keep me cool and give me the opportunity to be covered, but I can also lift the dress up to expose my legs if I want, since the sun helps my psoriasis.

I work in advertising and stand in front of people a lot to make presentations, says Joni. I make sure I have a loose cardigan or something that covers up my skin so that it doesnt take peoples attention away from what Im saying.

Even though I feel confident most of the time, there are still moments when I see someone looking at my skin or moving away from me and it takes me back to how I felt as a teenager, says Joni. In that moment, I tell myself that my psoriasis is a part of who I am. It has been around for all the major events in my life: graduating from college, getting married, and having my two daughters. Its part of what makes me, me.

You Might Also Like

Go here to read the rest:

My Psoriasis Doesnt Get in the Way of My Body Confidence - Yahoo Lifestyle

Psoriasis: Treatments, medication, symptoms and more – TODAY – TODAY

What is psoriasis? Psoriasis is a skin condition where your body makes new skin cells quickly. In about 80 to 90% of people with psoriasis, these skin cells build up in thick, scaly patches called psoriasis plaques, according to the American Academy of Dermatology (AAD). The condition is not contagious.

More than 8 million people in the U.S. have psoriasis, and it usually starts in the teen years or early 20s, though it can strike at any age, reports the National Psoriasis Foundation (NPF). It can develop in people of any race, and is more common in people who have a family member with the condition.

Dr. Carolyn Jacob, medical director of Chicago Cosmetic Surgery and Dermatology and a member of the American Academy of Dermatology (AAD), was diagnosed with psoriasis 36 years ago. Its what got me into dermatology, she said.

Untreated, people with psoriasis can leave a trail of unsightly scales that make them want to stay home. Most people dont care for that, said Dr. Amy McMichael, chair of the dermatology department at Wake Forest Baptist Health in North Carolina and a member of the American Academy of Dermatology. Now we can get those patients to where they have a very manageable disease.

Most people with psoriasis develop itchy, scaly plaques that are usually white or silver. They often crop up on the knees, elbows, lower back or scalp. On the scalp, they can spread to psoriasis of the face.

Less-common types of psoriasis can cause tiny pink bumps, skin thats sore and red, pus-filled bumps on the hands and feet or other skin problems. You can have more than one type of psoriasis.

Its also possible to have psoriasis with arthritis, where the psoriasis affects the joints. According to the NPF, 30 percent of people with psoriasis will go on to develop psoriatic arthritis.

Trending stories,celebrity news and all the best of TODAY.

What causes psoriasis? The immune system plays a role. With psoriasis, the white blood cells, or T-cells, in the bodys immune system attack the skin cells. The body responds by making more skin cells, which build up on top of the skin.

Theres also a genetic factor behind who gets psoriasis. But some people get psoriasis even though they dont have the genes that increase their risk, according to the AAD. And its possible that some people who do have the genes that increase their risk never develop psoriasis. Researchers think exposure to a trigger might kickstart psoriasis in people who are more likely to develop it.

There are certain triggers that can cause psoriasis for the first time. These triggers can also cause psoriasis flare-ups.

Triggers linked with psoriasis, according to the AAD:

Not every trigger causes flare-ups in every person with psoriasis, so its important to watch your symptoms and try to determine what could be causing them.

Your dermatologist will look over your skin, nails and scalp to check for signs of psoriasis, and ask about your symptoms, joint problems, family history and possible triggers.

Examining a skin sample under a microscope can help confirm a psoriasis diagnosis.

Psoriasis is almost always a lifelong condition. We dont have a cure, but we have many medications now that can make you feel like you dont have psoriasis, Jacob said. The medications have advanced so far since when I was diagnosed they used to call it the heartbreak of psoriasis.'

McMichael recalls an 18-year-old patient with severe psoriasis the plaques covered her body and she needed a wheelchair to get around. She had been through all the medications we had. Now you never see a patient like that, she said. Today, if one medication doesnt work there are a lot more to try. That has made the lives of psoriasis patients so much easier, she said.

According to the NPF, psoriasis treatment options include:

While todays treatments are highly effective, its often necessary to use a combination of different treatments to achieve clear or nearly clear skin and sometimes it can take months, or even years, to find a treatment regimen that works well for you, according to the NPF. But reducing your psoriasis is an important goal. Not only will it make your skin feel better, itll help improve your overall health, including any depression that may be related to your psoriasis; it can also reduce your risk of other conditions, such as diabetes and cardiovascular disease.

People with psoriasis and their providers can use the NPFs treatment targets for guidance on how soon results can be expected when trying out medication options. The NPF says that after 3 months on a medication, psoriasis should only appear on 1% or less of your body surface area, though 75% improvement is also acceptable. But if you havent reached 1% or less psoriasis on your body after 6 months on the treatment regimen (and if you havent had an acceptable response after 3 months), the NPF recommends discussing other treatment options with your doctor.

Additionally, if youve achieved success with a treatment regimen, but it stops working well, talk to your doctor about finding another treatment solution for your psoriasis.

Its one of my favorite skin conditions to treat because there are so many options to make it better, Jacob said. The new biologics work so well we can get peoples skin clear so they feel like they dont have psoriasis I forget I have it now.

See more here:

Psoriasis: Treatments, medication, symptoms and more - TODAY - TODAY

Psoriatic Arthritis Treatment Market Type, Share Size, Analysis Trends, Demand and Outlook 2028 – Cole of Duty

Global Psoriatic Arthritis Treatment Market: Overview

The demand within the global psoriatic arthritis treatment market has been rising on account of advancements in the field of healthcare and biosimilar analysis. The occurrence of psoriatic arthritis can place an extremely negative toll on the overall health of individuals. This is because psoriatic arthritis is more severe than any other form of arthritis. Under psoriatic arthritis, patients suffering from a skin condition called psoriases start to exhibit extreme symptoms of arthritis. This results in excessive pain, uneasiness, and discomfort for the sufferer, often necessitating emergency dosage of steroids. Hence, there is a dire need to ensure that psoriatic arthritis is controlled which in turn gives an impetus to the growth of the global market. The revenue scale of the global psoriatic arthritis treatment market shall improve alongside advancements in the field of geriatric care.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5495

There is no permanent treatment for psoriatic arthritis, and it can only be controlled with proper medication. The discomfort suffered by people affected with psoriatic arthritis is abysmal. Owing to the aforementioned factors, the global psoriatic arthritis treatment market is projected to attract the attention of the medical fraternity in the years to follow. The demand for psoriatic arthritis is projected to reach new heights in the years to follow.

The global psoriatic arthritis treatment market can be segmented on the basis of the following parameters: drug class, route of administration, and region. Based on drug class, the global psoriatic arthritis treatment market can be segmented into Disease-modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Antiinflammatory Drugs (NSAIDs), and biologics. Based on route of administration, the global psoriatic arthritis treatment market can be segmented into orals, topical, and injectables.

Global Psoriatic Arthritis Treatment Market: Notable Developments

Several advancement in the competitive landscape have become a key characteristic of the global psoriatic arthritis treatment market in recent times.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5495

Global Psoriatic Arthritis Treatment Market: Growth Driver

The occurrence of psoriatic arthritis is preceded by the severity of psoriasis in individuals. Hence, the field of dermatology needs to be work in conjunction with other medical departments in order to treat and control psoriatic arthritis. Hence, the global psoriatic arthritis treatment market shall expand alongside advancements in the field of dermatology. Furthermore, the availability of over-the-counter drugs for treatment of psoriatic arthritis propelled demand within the global market.

The joints suffer severe pain during psoriatic arthritis treatment, and the patients need to be quick recourse treatments. In a lot of cases, psoriatic arthritis poses a risk of permanent damage of joints. For this reason, the demand for psoriatic arthritis treatment has been rising at a stellar pace.

Global Psoriatic Arthritis Treatment Market: Regional Outlook

On the basis of geography, the global psoriatic arthritis treatment market can be segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Asia Pacific. The psoriatic arthritis treatment market in North America is expanding alongside advancements in the field of regional healthcare.

The global psoriatic arthritis treatment market can be segmented as:

Route of Administration

Read Comprehensive Overview of Report @https://www.tmrresearch.com/psoriatic-arthritis-treatment-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Link:

Psoriatic Arthritis Treatment Market Type, Share Size, Analysis Trends, Demand and Outlook 2028 - Cole of Duty

The Bidirectional Association Between Psoriasis & OSA – Physician’s Weekly

With psoriasis and obstructive sleep apnea (OSA) sharing various comorbidities and having a common pathogenesis of inflammatory and immune imbalance, many studies have examined the association between the two conditions. However, the results of these studies have differed. In order to evaluate the evidence on the bidirectional association of psoriasis and OSA, Ching-Chi Chi, MD, MMS, DPhil, Tzong-Yun Ger, MD, and Yun Fu, MD, conducted a systematic review and meta-analysis of case-control, cross-sectional, and cohort studies in the MEDLINE and Embase databases.

Exploring the Data

The researchers used the Newcastle-Ottawa Scale to evaluate the risk of bias of included studies and performed random-effects model meta-analysis to calculate pooled odds ratio (ORs) with 95% confidence intervals (CIs) for case-control and cross-sectional studies as well as pooled incidence rate ratio (IRR) with 95% CIs for cohort studies in association between psoriasis and OSA. Four case-control or cross-sectional studies and three cohort studies with a total of 5.8 million subjects were included.

Increased risk of OSA among patients with psoriasis was found in one cohort study, one cross-sectional study, and two case-control studies. Meta-analysis of the latter three showed a significant association of psoriasis with OSA among nearly 300,000 study subjects, with a pooled OR of 2.60, indicated that patients with psoriasis are 2.6-fold more likely to develop OSA when compared with patients without psoriasis, adds Dr. Ger (Figure 1). Although these three studies had considerable statistical heterogeneity, all had consistently positive results. In the cohort study, patients with mild psoriasis had a consistently increased risk of OSA (adjusted IRR, 1.36), as did those with severe psoriasis (adjusted IRR, 1.53) and psoriatic arthritis (adjusted IRR, 1.98).

Conversely, a consistent increase in psoriasis among patients with OSA was found across three cohort studies and one case-control study. A meta-analysis of the cohort studies showed a significant association of OSA with psoriasis (polled IRR, 2.52) across more than 5.5 million study subjects, with no statistical heterogeneity within the studies (Figure 2). After excluding one study with a high risk of bias in the representativeness of the exposed cohortall were nursesthe association of OSA with psoriasis remained positive (pooled IRR, 2.47). A significantly increased odds for psoriasis in relation to OSA was seen in the one case-control study (adjusted OR, 13.31).

Looking Ahead

Drs. Ger and Chi note the need for future research investigating the relationship between OSA and psoriasis in patients with varying races/ethnicities and from various regions, as well as the need for studies to confirm the mechanism(s) behind the relationship between the two conditions.

In the meantime, Dr. Ger suggests that all patients with psoriasis be made aware of their increased risk for OSA as a comorbidity that should not be overlooked. This patient population should be asked about sleep quality, and those with snoring at night, daytime sleepiness, and insomnia should be considered for polysomnography, consultation with a pulmonologists, or both. On the other hand, physicians should inquire about skin problems with their patients with OSA. Those suspected of having psoriasis should be referred to a dermatologist for further evaluation and treatment.

Bidirectional Association Between Psoriasis and Obstructive Sleep Apnea: A Systematic Review and Meta-Analysishttps://www.nature.com/articles/s41598-020-62834-x

See the article here:

The Bidirectional Association Between Psoriasis & OSA - Physician's Weekly

Superior Skin Clearance Observed With Risankizumab in Head-to-Head Psoriasis Study – Monthly Prescribing Reference

New data from a head-to-head study comparing risankizumab-rzaa to secukinumab in patients with moderate to severe plaque psoriasis were recently presented online at the American Academy of Dermatology virtual annual meeting.

In this 52-week, phase 3b, open-label, active-comparator study, patients were randomized to receive risankizumab 150mg subcutaneously (n=164) at baseline, week 4, then every 12 weeks thereafter, or secukinumab 300mg subcutaneously at baseline, weeks 1, 2, 3, and 4, then every 4 weeks thereafter. The co-primary end points were the proportion of patients with a 90% reduction in the Psoriasis Area and Severity Index score (PASI 90 response) at week 16 (noninferiority) and at week 52 (superiority) from baseline.

Results showed that the study met both primary end points of noninferiority and superiority. A greater proportion of patients treated with risankizumab achieved a PASI 90 response at week 16 (74% vs 66%) and at week 52 (87% vs 57%; P <.001) compared with secukinumab.

Risankizumab also met key secondary end points including a superior rate of complete skin clearance (PASI 100 response) at week 52 compared with secukinumab (66% vs 40%; P <.001). Moreover, 88% of patients treated with risankizumab achieved a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) at week 52 compared with 58% of patients treated with secukinumab (P <.001).

Risankizumab and secukinumab demonstrated comparable rates of adverse reactions. The most common were nasopharyngitis, upper respiratory tract infection, headache, arthralgia and diarrhea.

Risankizumab, an interleukin-23 antagonist, is marketed under the trade name Skyrizi and is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Secukinumab, an interleukin-17A antagonist, is marketed under the trade name Cosentyx and is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also approved for the treatment of active psoriatic arthritis or ankylosing spondylitis in adults.

For more information visit abbvie.com.

See original here:

Superior Skin Clearance Observed With Risankizumab in Head-to-Head Psoriasis Study - Monthly Prescribing Reference

Global Psoriasis Drugs Industry Market Overview, Cost Structure Analysis, Growth Opportunities and Forecast to 2027 – 3rd Watch News

With having published myriads of reports, Psoriasis Drugs Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts delivers reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available to provide custom-made business solutions to the clients.

In this new business intelligence report, Psoriasis Drugs Market Research serves a bunch of market forecast, structure, potential, and socioeconomic impacts associated with the global Psoriasis Drugs market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Psoriasis Drugs market.

Get Free sample copy of this report, @https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-psoriasis-drugs-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/148089#request_sample

The Psoriasis Drugs market report has been fragmented into important regions that showcase worthwhile growth to the vendors. Each geographic segment has been measured based on supply-demand status, distribution, and pricing. Further, the study brings information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

The following manufacturers are covered:

Takeda PharmaceuticalJanssen BiotechMerckUCBBiogenAbbvieCelgene CorporationEli Lilly & CompanyAmgenAbbVieJohnson & JohnsonAstraZenecaNovartis AGStiefel LaboratoriesPfizer

Segment by Regions

North America

Europe

China

Japan

Southeast Asia

India

Market Segmentation based on Type:

Tumor Necrosis Factor InhibitorInterleukin InhibitorsOthers

Market Segmentation based on Application:

Plaque PsoriasisGuttate PsoriasisInverse PsoriasisPustular PsoriasisErythrodermic Psoriasis

Get Your Copy at a Discounted Rate!!!

Ask For Discount https://www.globalmarketers.biz/discount_inquiry/discount/148089

Segmentation of the Psoriasis Drugs market to target the growth outlook and trends affecting these segments.

Make An Enquiry About This Report @What does the Psoriasis Drugs market report contain?

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-psoriasis-drugs-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/148089#inquiry_before_buying

Readers can get the answers of the following questions while going through the Psoriasis Drugs market report:

Browse the complete report @https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-psoriasis-drugs-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/148089#table_of_contents

See the original post here:

Global Psoriasis Drugs Industry Market Overview, Cost Structure Analysis, Growth Opportunities and Forecast to 2027 - 3rd Watch News

Psoriasis Treatment Market Presents an Overall Analysis, Trends and Forecast to 2025 – 3rd Watch News

Global Psoriasis Treatment Industry Market, 2020-2025 Research Report provides crucial statistics on the market status of the Global Psoriasis Treatment Industry manufacturers and is a respected source of guidance and direction for companies and individuals interested in the industry.

This Psoriasis Treatment Industry market research study is a collection of insights that translate into a gist of this industry. It is explained in terms of a plethora of factors, some of which include the present scenario of this marketplace in tandem with the industry scenario over the forecast timeframe.

Request a sample Report of Psoriasis Treatment Industry Market at:https://www.marketstudyreport.com/request-a-sample/2728907

The report is also inclusive of some of the major development trends that characterize the Psoriasis Treatment Industry market. A comprehensive document in itself, the Psoriasis Treatment Industry market research study also contains numerous other pointers such as the current industry policies in conjunction with the topographical industry layout characteristics. Also, the Psoriasis Treatment Industry market study is comprised of parameters such as the impact of the current market scenario on investors.

The pros and cons of the enterprise products, a detailed scientific analysis pertaining to the raw material as well as industry downstream buyers, in conjunction with a gist of the enterprise competition trends are some of the other aspects included in this report.

How has the competitive landscape of this industry been categorized?

Regional landscape: How will the details provided in the report help prominent stakeholders?

Ask for Discount on Psoriasis Treatment Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2728907

Other pivotal aspects encompassed in the Psoriasis Treatment Industry market study:

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-psoriasis-treatment-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Transplant Diagnostic Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-transplant-diagnostic-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global Cloud Kitchen Foodservice Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-cloud-kitchen-foodservice-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read more:

Psoriasis Treatment Market Presents an Overall Analysis, Trends and Forecast to 2025 - 3rd Watch News

UCB flashes the data behind its positive psoriasis readouts. Can it compete in a crowded field? – Endpoints News

Eight months after UCB announced that a little-watched drug candidate outperformed J&Js blockbuster Stelara, the Belgian pharma is out with full data that one investigator calls remarkable.

In the Phase III trial, 58.6% of patients who took UCBs IL-17 blocker bimekizumab were completely cleared of skin lesions after 16 weeks, compared to 20.9% of patients on Stelara. The UCB drug also outperformed Stelara at how many patients were clear after one year and at lesser benchmarks for plaque clearance, with more than 8 out of 10 patients showing 90% improvement, compared to roughly half on Stelara.

In a second study, first announced positive in November, bimekizumab was compared to placebo. In that one, 68% of patients on the treatment arm saw their skin completely clear and over 90% saw a 90% improvement. For placebo that number was 1.2%.

It really showed some quite impressive, remarkable I dont know how you want to say it, but extremely high level of responses, Kenneth Gordon, lead investigator on the placebo-controlled study, told Endpoints News.

Gordon singled out a couple distinct characteristics about the responses that stood out. Those included how sweepingly the drug alleviated symptoms, how quick it did so, and how long it lasted.

If you compare it to other clinical trials programs, both the speed and magnitude of the responses were around the highest weve seen, Gordon said.

Researchers often caution against comparing different clinical trials, such comparisons will be crucial for a drug like bimekizumab. The plaque psoriasis is a highly competitive market, suffuse with approved biologics from some of the worlds biggest drugmakers. Stelara is just one of several options patients can currently choose from.

The new data were released in abstracts for the annual American Academy of Dermatology meeting. On Friday afternoon, AbbVie also released abstracts from its open-label Phase III trial testing Skyrizi, an IL-23 inhibitor approved last year for psoriasis, against Novartis Cosentyx.

While trouncing Cosentyx, Skyrizi showed a virtually identical ability as UCBs drug to clear plaque psoriasis after one year: 66%. In addition, Eli Lillys IL-17 inhibitor beat J&J Tremfya last year in a head to head trial on psoriasis. UCB also beat AbbVies Humira last year, although results have yet to be announced.

From a medical perspective, though, Gordon suggested that asking which one is best might not be the best approach. Instead, prescribing decisions may come down to matching individual patients to the best drug.

Bimekizumab blocks multiple cytokines involved in plaque psoriasis, IL-17a and IL-17f. Because IL-17f exists in greater quantities in plaques, but IL-17a is more active, it had been an open question whether it was best to blockade both or if you could just target one and have the same effect.

Though cautioning no trial has been completed, Gordon said the latest data seem to resolve that debate. He argued the new insight, along with some of the other new molecules, represented a capstone on the progress the field has made since the chemotherapy drug methotrexate was first given to modest effect in the 1950s.

This might be culminating biologic molecule for psoriasis we have in the near future, he said. Now the question is how can we best apply each of our medications.

Read this article:

UCB flashes the data behind its positive psoriasis readouts. Can it compete in a crowded field? - Endpoints News

U.S. Dermatology Partners Georgetown, formerly Georgetown Dermatology & Skin Cancer Center, is pleased to announce the addition of David Ettinger,…

Dermatology PA, David Ettinger joins U.S. Dermatology Partners Georgetown

GEORGETOWN, Texas (PRWEB) June 22, 2020

U.S. Dermatology Partners Georgetown is excited to welcome David Ettinger, PA-C. Born and raised in the state of Washington, David relocated after high school and has lived in California, Arizona, and South America. He attended Northern Arizona University to obtain his Bachelor of Science before earning his Master of Physician Assistant Studies at the University of Washington School of Medicine in Seattle.

Since graduating, David Ettinger has worked in dermatology and craniofacial reconstructive plastic surgery with a focus in pediatrics. He loves dermatology and helping others feel more comfortable in their skin and providing relief to those struggling with various skin conditions.

He has participated in clinical research trials for psoriasis and "Spray-on Skin" to determine their efficacy and safety in the pediatric population. "It has been wonderful to be part of the process to find new ways to treat and provide relief to those suffering", says David, a member of the Society of Dermatology Physician Assistants (SDPA).

As a physician assistant with several years of dermatology experience, David will treat patients with medical dermatology concerns such as acne treatment, psoriasis, rosacea, and eczema. He welcomes both adult and pediatric patients at our Georgetown, Texas dermatology clinic.

David Ettinger feels lucky to be raising 3 energetic, loving children alongside his wife. They enjoy spending time on the lake, exercising, and watching their children participate in their weekend sporting events.

U.S. Dermatology Partners Georgetown has been serving the dermatology needs of Georgetown and the Central Texas community since 2003. Founded by Dr. Kevin Miller, the Georgetown dermatology group includes Board-Certified Dermatologists, Dr. Monica Madray, Dr. Elizabeth Morris, Dr. Weilan Johnson, Fellowship-Trained Mohs Surgeon, Dr. Nicholas Snavely, Certified Physician Assistant David Ettinger, PA-C, and Licensed Aesthetician Corey Stoever, LA.

The state-of-the-art dermatology office was expanded in 2011 to meet the growing patient demand. U.S. Dermatology Partners Georgetown offers a full suite of clinical and surgical services, including Mohs surgery for the treatment of skin cancer. The providers treat conditions like acne, psoriasis and eczema to relieve or improve symptoms that limit your comfort, health and enjoyment. We provide specialized, highly effective treatments for a variety of skin cancers to restore and extend the quality of your life. The providers, who are parents of young children, feel comfortable treating patients of all ages, from the very young to the retirees of the Sun City community.

For more information or to schedule a new appointment, please contact the office at (512) 819-9910.

About U.S. Dermatology Partners

As one of the largest physician-owned dermatology practices in the country, U.S. Dermatology Partners' patients not only have access to general medical, surgical, and cosmetic skin treatments through its coordinated care network, but also benefit from the practice's strong dermatology subspecialty thought leaders and medical advisory board. To be the best partners to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team, therefore, includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery. To learn more, visit usdermatologypartners.com.

For the original version on PRWeb visit: https://www.prweb.com/releases/u_s_dermatology_partners_georgetown_formerly_georgetown_dermatology_skin_cancer_center_is_pleased_to_announce_the_addition_of_david_ettinger_pa_c_june_22nd/prweb17207222.htm

Read more here:

U.S. Dermatology Partners Georgetown, formerly Georgetown Dermatology & Skin Cancer Center, is pleased to announce the addition of David Ettinger,...

Melanoma Risk and Biologic Therapy: Is There a Link? – Cancer Therapy Advisor

Immune-mediated inflammatory conditions such as inflammatory bowel disease (Crohn disease [CD], ulcerative colitis [UC]), psoriasis, and rheumatoid arthritis (RA) are frequently treated with antitumor necrosis factor-alpha (TNF-) agents. TNF- inhibitors (TNFIs) have shown significant clinical safety and efficacy profiles in these inflammatory conditions; however, the potential risks of long-term use are a consistent concern of both physicians and patients.

As the TNF- pathway plays a critical role in tumor surveillance, there is concern that inhibition of this pathway could predispose patients to certain malignancies.1 One such cancer that is of great concern with respect to the TNF- pathway is melanoma.1 As the use of TNFIs and other biologics have grown increasingly popular, there has been noteworthy research interest in the actual risk of melanoma in these patients.

When evaluating a study estimating the risk of melanoma in patients receiving TNFIs, it is critical to determine if the comparison group is either the general population or patients with inflammatory conditions treated with other systemic therapy. There is a meager number of studies specifically evaluating the latter, especially studies with IBD and psoriasis. Interestingly, Esse and colleagues recently published a systematic review and meta-analysis in JAMA Dermatology specifically evaluating the risk of melanoma in patients with IBD, RA, and psoriasis who were treated with biologic therapy compared to those who had received only other conventional systemic therapy.2

The authors identified 7 studies, all of which were published between 2007 and 2019, and were cohort studies that were conducted in several countries (United States, Denmark, Sweden, and Australia). These studies included a total of 34,029 patients who received biologic therapy compared with 135,370 biologic-naive patients who had received conventional systemic therapy. Mean patient-follow duration ranged from 1 year to 5.48 years. Most studies included TNFIs, however, there were some patients receiving abatacept and rituximab were also included in the meta-analysis.

There were no significant differences found in the pooled relative risk (pRR) estimates for patients treated with biologic therapy compared with those who were treated with conventional therapy in IBD (pRR, 1.20; 95% CI, 0.60-2.40) and RA (pRR, 1.20; 95% CI, 0.83-1.74).

All of the included studies were considered high-quality studies, according to the review authors, and there was no evidence of publication bias or significant heterogeneity in the studies across the patient groups. When specifically looking at each biologic agent individually (TNFIs, abatacept, rituximab), there remained no statistically significant difference in melanoma risk when compared with patients receiving conventional therapy. If individual RA studies were excluded, sensitivity analyses showed that the pRR continued to not be statistically significant from patients receiving conventional therapy.

A key distinguishing factor of this study was inclusion of patients with inflammatory conditions whom were biologic naive and their comparison with those receiving standard therapies. This study is interesting to juxtapose with several prior studies evaluating similar melanoma outcomes. Singh and colleagues published a similar systemic review and meta-analysis in Clinical Gastroenterology and Hepatology in 2014 that specifically evaluated the risk of melanoma in patients with IBD.3 This review evaluated 12 studies that included 172,837 patients with IBD and found a pooled crude incidence rate (IR) of melanoma in patients with IBD of 27.5 cases per 100,000 person-years (95% CI, 19.9-37). Overall, IBD was associated with a 37% increased risk of melanoma. This relative risk was higher in those patients with CD (RR, 1.80; 95% CI, 1.17-2.75) compared with those with UC (RR, 1.23; 95% CI, 1.01-1.50). This increased risk of melanoma was found to be independent of biologic therapy.

Another systematic review published by Peleva and colleagues in the British Journal of Dermatology in 2018 evaluated 8 prospective cohort studies evaluating the risk of all cancers in patients with psoriasis who were treated with biologic therapies.4 The authors found an increase in nonmelanoma skin cancer (NMSC) particularly squamous cell carcinoma but there was no evidence of increased risk of melanoma. This review was limited by the inclusion of only 1 study evaluating melanoma risk in patients treated with ustekinumab.

Read more from the original source:

Melanoma Risk and Biologic Therapy: Is There a Link? - Cancer Therapy Advisor

Skin Picking: How to Manage and Treat the Stress Disorder – Coveteur

How to address excoriation disorder during extreme stress.

I thought the office was empty, but it wasnt. I turned a corner and found a lone coworker with an embarrassed look on his face. He, too, thought he was alone, so hed picked at a pimple on his face, which was now bleeding. I felt his pain, since at the time I was suffering from the worst bout of adult acne Id ever had. My one reprieve was going to the office each day, where I had no choice but to keep my hands off my face.

After countless workers began working from home this spring, my friends have gradually revealed that theyre all struggling with the same issuethey cant stop picking at their faces. And who can really blame them? Tensions are high, to say the least, and recent events are triggering more cortisol (your fight-or-flight hormone) to flood our systems and incite stress responses, like excoriation disorder.

Also known as chronic skin picking or dermatillomania, excoriation disorder is related to obsessive-compulsive disorder and involves repeatedly picking at the skin, which can cause painful lesions as well as a disruption to daily life. Not all forms of skin picking fall into this more serious categoryin fact, most dontbut expert insight into both the causes and healing process can help anyone compulsively picking at their skin, hair, nails, or scabs begin to move forward on the path to recovery.

Advertisement

Stress, stress, and more stress. Dr. Nancy Irwin, a licensed clinical psychologist, confirmed that the immense amount of stress and anxiety many people are experiencing right now are playing a two-pronged rolethey can both cause acne to develop and drive the desire to pick. Dr. Irwin noted that stress is behind about 72 percent of all illnesses and conditions, skin related or not. As the skin is our largest organ, it can hold clues as to what the person is feeling about the self and/or life at the current time, Dr. Irwin explains. The negative effects of stress on skin can manifest in conditions like acne, dandruff, itchy skin, and even hair loss. Stress can also cause flare-ups of skin issues such as psoriasis and rosacea to occur.

She notes that skin picking can become a compulsion if you do not identify the root of the problem, as well as make lifestyle changes that help you better manage your stress levels. Having a positive support system and making time for fun and self-care are a good place to start. These can involve exercising and eating healthy, enjoying leisure activities, or practicing your faith or meditation. We all have varying degrees of stress and challenges, so Dr. Irwin encourages patients to have a go-to list of how you can self-soothe and process those stressors when they present themselves. Work on building up trust in yourself that you have everything you need to weather the current challenges.

We know that picking at acne lesions, dry skin, or any part of our bodies can damage the skin, resulting in hyperpigmentation, multiple forms of scarring, disfigurement from lesions, and open wounds that might lead to further infection. Stopping the impulse to do so is easier said than done, however. Everything has a positive intent, and picking is a relief of anxiety, Dr. Irwin clarifies. But that doesn't mean its a healthy coping mechanism, [Patients that pick] are avoiding the issue [causing their stress] and compounding the belief that there is no other way to manage the pain or issue at hand.

One tactic for managing the urge to pick that Dr. Irwin recommends is asking yourself empowering questions likeIf I were able to handle this stress in my life while respecting my body, how would I do so? Who do I know that can help me? Another is seeking the counsel of those who have overcome picking-related struggles, such as in a support group. You are not alone. There are millions of others who have suffered this and overcome it. They can be excellent resources for you. If you are looking for professional help, Dr. Irwin suggests working with a therapist who concentrates in this area.

Advertisement

Skin-picking disorder impacts as many as one in twenty people, with women being more commonly affected than men. After you identify the source of your stress and anxiety and seek treatment, the next step is healing the preexisting damage. Dr. Annie Chiu, board-certified cosmetic and general dermatologist, concedes that right now is an especially hard time to stop picking at your skin. She explains that stress weakens our skin barrier, which is why most skin conditions (like acne and psoriasis) tend to flare up during those moments. More lesions means you have more opportunities to pick. When you have good skin, its just not as tempting, she notes.

Weve all tried to pop the occasional pimple that we should have left alone, and watched it heal slower as a result, but serious cases of excoriation disorder can lead to more serious damage, like tissue injury, scarring, and discoloration. To heal the physical effects of picking or more extreme cases of excoriation disorder, Dr. Chiu recommends using a gentle facial cleanser followed by a soothing balm or serum to maintain skin hydration. She suggests reaching for any occlusive protectant (aka slippery balm-type products) like Aquaphor to help skin cells heal faster and create a protectant barrier. Look for ingredients such as ceramides, niacinamide, or hyaluronic acid, all of which can help build skin-health barriers. She also recommends incorporating overnight moisturizing masks and sheet masks into your skin-care routinebut be sure not to go overboard on new products, as tempting as it can be to try everything under the sun.

To address the breakouts themselves, Dr. Chiu is a fan of acne patches to cover the zit, such as COSRX Acne Pimple Master Patch, which physically blocks you from picking and contains acne-fighting ingredients like tea tree oil and salicylic acid. Says Dr. Chiu, If were actively conscious were taking care of our skin, we are not going to be as prone to want to ruin that. For those looking to heal deeper scarring, there are also in-office solutions such as cortisone injections and laser treatments. Your dermatologist will be able to recommend the best course of action depending on your current skin condition.

Below, five of our favorite products to help heal breakouts, soothe the skin, and repair damage from previous picking.

Read the rest here:

Skin Picking: How to Manage and Treat the Stress Disorder - Coveteur

Are Patients With Psoriasis at Increased Risk for Serious Infection, Hospitalization? – Dermatology Advisor

Psoriasis is associated with increased risk for serious infection, according to the results of cohort study data published in the British Journal of Dermatology. During 5 years of follow-up, patients with psoriasis were more often hospitalized for infections than individuals without psoriasis.

Investigators conducted a cohort study of adults (18 years) with and without psoriasis using the United Kingdom Clinical Practice Research Datalink (CPRD). CPRD data were linked to hospital and mortality records in the United Kingdom for the years 2003 to 2016. Patients with psoriasis were matched with up to 6 control patients by age, sex, and place of clinical care. History of hospitalization was ascertained from the Hospital Episode Statistics database; death was ascertained from Office of National Statistics mortality records. Stratified Cox proportional hazard models were used to examine the relationship between psoriasis, hospitalization, and mortality. Models were adjusted for age, economic deprivation, body mass index, alcohol intake, smoking status, and comorbid conditions.

The study cohort comprised 69,312 patients with psoriasis and 338,598 comparators. Patients and comparators were followed for a median (interquartile range) of 4.9 (5.9) and 5.1 (6.3) years, respectively. The incidence rate of serious infection was 20.5 per 1000 person-years (95% confidence interval [CI], 20.0-21.0) in patients with psoriasis and 16.1 per 1000 person-years (95% CI, 15.9-16.3) in comparators. The fully adjusted hazard ratio (HR) for hospitalizations due to infection was 1.36 (95% CI, 1.31-1.40) in patients with psoriasis vs comparators. When analyses were stratified by infection type, patients with psoriasis had the highest HR for skin and soft-tissue infections (HR, 1.56; 95% CI, 1.43-1.70). Risk for respiratory infections was also increased (HR, 1.35; 95% CI, 1.27-1.44). Death due to any infection was also more common in patients vs control patients (HR, 1.33; 95% CI, 1.08-1.63).

Although the absolute risk for serious infection in patients with psoriasis was small, the likelihood of hospitalization and death were nonetheless increased compared with control patients. Future research is necessary to explore the mechanism by which psoriasis increases risk for certain infections, particularly soft-tissue and respiratory infections. As study limitations, investigators noted the risk for residual confounding and detection bias implicit in using hospital records. Increased psoriasis severity did not appear to influence risk for infection, suggesting that disease severity may have not been properly captured. Despite those findings, these results provide evidence for an increased risk for serious infection and hospitalization in patients with psoriasis.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry.

Please see the original reference for a full list of authors disclosures.

Follow @DermAdvisor

Reference

Yiu ZZN, Parisi R, Lunt M, et al . Risk of hospitalisation and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink [published online March 28, 2020]. Br J Dermatol. doi: 10.1111/bjd.19052

Go here to see the original:

Are Patients With Psoriasis at Increased Risk for Serious Infection, Hospitalization? - Dermatology Advisor